↓ Skip to main content

Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy

Overview of attention for article published in International Journal of Cancer, November 2013
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (76th percentile)
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

policy
1 policy source
twitter
2 tweeters

Citations

dimensions_citation
64 Dimensions

Readers on

mendeley
60 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy
Published in
International Journal of Cancer, November 2013
DOI 10.1002/ijc.28576
Pubmed ID
Authors

Michael Weller, Kerstin Kaulich, Bettina Hentschel, Joerg Felsberg, Dorothee Gramatzki, Torsten Pietsch, Matthias Simon, Manfred Westphal, Gabriele Schackert, Joerg C. Tonn, Andreas von Deimling, Thomas Davis, William Andrew Weiss, Markus Loeffler, Guido Reifenberger

Abstract

The epidermal growth factor receptor vIII mutant (EGFRvIII) is found in ~50% of all EGFR-amplified glioblastomas and constitutes a tumor-specific therapeutic target. To assess molecular testing approaches and the prognostic role of EGFRvIII in patients treated according to current standards of care, we compared different EGFRvIII detection methods and correlated EGFRvIII status with outcome in a prospective patient cohort of the German Glioma Network. In total, 184 newly diagnosed glioblastoma patients were investigated for EGFR amplification and for expression of EGFR and EGFRvIII by immunohistochemistry. Further, the EGFRvIII status was additionally studied by multiplex ligation-dependent probe amplification (MLPA) analysis and reverse transcription-PCR (RT-PCR). Immunohistochemistry demonstrated EGFRvIII in 34 of 184 patients (18%). RT-PCR or MLPA analysis detected four additional EGFRvIII-positive patients. Overall, RT-PCR and immunohistochemistry were more sensitive for EGFRvIII detection than MLPA. EGFRvIII status was not associated with progression-free and overall survival. EGFRvIII also had no prognostic significance in the subgroup of patients who were free from progression after concomitant radiochemotherapy and thus would be eligible for the ongoing ACT IV EGFRvIII vaccination trial. Age, extent of resection and O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status appeared to be less prognostic in EGFRvIII-positive patients. Thus, EGFRvIII positivity is not a major negative prognostic factor in glioblastoma patients treated according to current standards of care. Data from phase II EGFRvIII-targeted vaccination trials compare favorably with the present contemporary results, supporting the further exploration of EGVRvIII vaccination in newly diagnosed glioblastoma.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 2%
Unknown 59 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 9 15%
Student > Ph. D. Student 9 15%
Student > Doctoral Student 7 12%
Researcher 7 12%
Student > Postgraduate 6 10%
Other 13 22%
Unknown 9 15%
Readers by discipline Count As %
Medicine and Dentistry 19 32%
Agricultural and Biological Sciences 9 15%
Neuroscience 8 13%
Biochemistry, Genetics and Molecular Biology 7 12%
Immunology and Microbiology 1 2%
Other 6 10%
Unknown 10 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 July 2018.
All research outputs
#3,278,852
of 13,205,256 outputs
Outputs from International Journal of Cancer
#2,693
of 9,201 outputs
Outputs of similar age
#43,034
of 189,094 outputs
Outputs of similar age from International Journal of Cancer
#24
of 101 outputs
Altmetric has tracked 13,205,256 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 9,201 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 189,094 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 101 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.